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Abstract
HIV infection can contribute to disturbances in both linear growth and weight gain in early
childhood, with disturbances often apparent as early as 3 mo of age. There is little evidence for a
difference in the early growth of HIV-exposed but uninfected children compared to healthy
controls. Owing to the close association of growth with immune function and clinical progression,
an understanding of growth patterns may be an important tool to ensure the provision of
appropriate care to HIV-infected and exposed children. Timely growth monitoring may be used to
improve the clinical course and quality of life of these children.
Keywords
HIV; child; postnatal growth
Introduction
The HIV/AIDS pandemic is one of the most important challenges in global health today. In
2007, 33 million people worldwide were estimated to be living with HIV.1 The epidemic in
much of the world has been concentrated among populations most at-risk, such as men who
have sex with men, injection drug users, sex workers and their sexual partners. In sub-
Saharan Africa, home to more than two out of every three infected people, the HIV/AIDS
epidemic has been sustained in the general population and resulted in increased burdens of
disease for both women and children. The majority of people living with HIV in sub-
Saharan Africa are women, and nearly 90% of children infected with HIV live in this region.
1
HIV infection in children is generally due to vertical transmission either during the antenatal
and perinatal periods or through breastfeeding. Most studies suggest no difference in the
birth size of HIV-positive and negative children born to HIV-infected women, as HIV
transmission appears to occur late in gestation.2 Infection can, however, contribute to
disturbances in both linear growth and weight gain in early childhood. Growth failure is now
recognized as one of the most common manifestations of HIV infection in children, with
failure to thrive reported in 20–70% of infected children.3 Contributing to the onset of
immune deficiency and opportunistic infection, impaired growth is a sensitive indicator of
morbidity and mortality in HIV-infected children.4, 5
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A number of longitudinal studies have now explored the association between HIV and
postnatal growth over time and described a variety of disturbed growth patterns. Differences
in observed growth patterns may result from underlying differences in the populations
studied, including differences in prenatal growth patterns, the availability of anti-retroviral
(ARV) therapy, food supplementation or socioeconomic conditions, or from differences in
disease manifestation due to virus sub-types, prevalence of sexually transmitted diseases
(STD) or nutritional deficiencies.
In this review, we focus on studies that have examined the association of HIV infection or
HIV exposure with postnatal growth over time. We review all longitudinal studies
conducted to date, summarize the evidence relating HIV infection and HIV exposure to
growth in children, and suggest clinical and research implications and priorities.
Methods
The patterns of postnatal growth are described in three groups of children defined as
follows: 1) HIV-infected children, the majority of which are infected perinatally during late
pregnancy and delivery or postnatally during breastfeeding. A small proportion of HIV-
infection children acquire HIV through other routes, including transfusion with blood or
blood products; 2) children exposed to but not infected with HIV; these children, referred to
as sero-reverters, are born to HIV-infected mothers but are not HIV-positive themselves; and
3) healthy controls, including children without HIV exposure or infection born to HIV-
negative mothers. The impact of HIV infection is evaluated by summarizing differences in
postnatal growth in HIV-infected children vs. sero-reverters, and the impact of HIV
exposure is evaluated by summarizing differences in sero-reverters vs. healthy controls.
Studies included in this review were identified through a PubMed search of the literature.
All papers published from January 1, 1985 to January 1, 2009 were identified by use of the
term “HIV” together with the term “child growth.” Inclusion criteria were as follows: 1)
outcomes included anthropometric indices/velocity (e.g. height, weight, head circumference,
height-for-age, weight-for-age, weight-for-height, body mass index (BMI)) or body
composition measures (e.g. triceps skinfold thickness, arm muscle circumference, fat free
mass, or body cell mass); 2) “exposure” groups included HIV-infected children, sero-
reverters and/or HIV-uninfected children born to HIV-negative mothers; 3) longitudinal
design; and 4) publication in the English language. The focus of this review was limited to
longitudinal studies in order to describe postnatal growth dynamics associated with HIV
infection and HIV exposure over time. Case reports and studies on the effects of
antiretroviral treatment were not included.
Papers meeting the inclusion criteria were reviewed to extract information on study design,
exposure and outcome measurement methods, statistical techniques, confounding factors
and results. The literature cited in papers recovered through the initial PubMed search was
also reviewed to supplement the originally identified publications. All relevant studies are
summarized by study setting (i.e. economically ‘developed’ countries including the United
States, Europe and Australia vs. economically ‘less developed’ countries including those of
Latin America, sub-Saharan Africa, and Asia) to facilitate the identification of possibly
different patterns of postnatal growth and to separate the confounding effects of differing
levels of treatment and care from the exposure of interest. Results are presented separately
for the impact of HIV infection (HIV-infected children vs. sero-reverters) and for the impact
of HIV exposure (sero-reverters vs. healthy controls) on postnatal growth. Results from
studies that include all 3 groups of children are included in both 2-group comparisons.
Results from studies describing the postnatal growth of HIV-infected vs. HIV-uninfected
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children (without determination of the uninfected child’s HIV exposure status) are presented
with results on the impact of HIV infection.
Epidemiological Evidence
The initial PubMed search identified 845 publications, from which 37 were ultimately
identified as longitudinal studies that examined the association of HIV infection or exposure
with postnatal growth. From the identification of first pediatric case of HIV in the early
1980’s to 1990, only 1 study was identified through this review that considered the
association between HIV status of children and postnatal growth.6 The 1990’s saw an
increase in evidence for an association between HIV status and growth in children, with 24
new research papers published on this issue between 1990 and 2000. 4, 7–29 Many of these
early reports were from populations in the United States and Europe. Data on the
anthropometric characteristics of HIV-infected and HIV-exposed children in other settings,
including sub-Saharan Africa, largely became available only in the latter half of the 1990’s.
4, 7, 8, 17, 18
Developed countries
HIV infection and postnatal growth—Seventeen studies compared the postnatal
growth of HIV-infected and HIV-exposed but - uninfected children in developed countries
(Table 1). All studies were from the United States or Western Europe and the mean duration
of follow-up ranged from 4 mo to 10 years.
Linear growth—Of the 13 papers to examine the association of infection status with
height, 11 provided supportive evidence of lower height-for-age among HIV-infected
children compared to sero-reverters. 9, 12–14, 19, 21, 24, 27, 29–31 In studies in which an
association was found and results reported, the difference in height-for-age Z score between
HIV-infected children and sero-reverters ranged from −0.73 to −0.90 Z at 12 mo and −0.31
to −0.91 Z at 18 mo after birth. In studies where differences in height (cm) were presented,
differences were small and between 1 and 3 cm through 4 ys of age.12, 21, 30 At 10 ys of
age, the European Collaborative Study observed a difference of −7.6 cm in heights of HIV-
infected children vs. sero-reverters.31 Impairment in height-for-age was most often noted
within 3–4 mo after birth.9, 14, 19, 21, 27, 29–31 but also seen at 15 mo.13 Early
differences in height-for-age were found to persist 19, 21, 24, 30 or increase through follow
up.9, 14, 31 HIV-infected children, compared to sero-reverters, were also found to have
increased risks of linear growth failure (defined as HAZ < −2, growth < 4 cm/y or height
deceleration of > 10%; 27% vs. 12.8%)32, stunting (7/18 vs. 1/29)29 and failure to thrive
(IRR = 3.9).23 One multi-site study from the United States did not support an association
between HIV infection and lower height-for-age 19–21 mo after birth.15 Similarly, no
difference was found in mean height before vs. after HIV sero-conversion in a small group
of hemophiliac boys.25
Weight gain—The same 13 studies evaluated the association of HIV infection with
weight-for-age, 10 of which reported significantly lower weight-for-age in HIV-infected
children than in sero-reverters. 9, 12–15, 21, 24, 27, 30, 31 In the studies in which an
association was found and results reported, the difference in weight-for-age Z score between
HIV-infected children and sero-reverters ranged from −0.81 to −0.92 Z at 6 mo, −0.55 to
−0.91 Z at 12 mo, −0.77 to −0.98 Z at 18 mo, and −0.57 Z at 24 mo after birth. Differences
in weight (kg) were less than −1.5 kg through 4 ys of follow up.12, 21, 30 Compared to
sero-reverters, HIV-infected children were lighter by 0.61 to 0.65 kg at 6 mo, 0.75 kg at 12
mo, 0.63 kg at 24 mo, and 0.71 to 0.90 kg at 48 mo after birth. After 10 ys of follow up,
HIV-infected children in the European Collaborative Study were 6.95 kg lighter than sero-
reverters.31 Two smaller studies by Pollack et al19, 29 did not support a link between HIV
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infection and weight, either as median weight, weight-for-age Z or number underweight
with 18 mo of follow up, and the ratio of weight to 50th centile for age 25 and weight
velocity24 did not differ by HIV infection status in 2 other small studies. Of the 8 papers in
which both lower height-for-age and weight-for-age among HIV-infected children were
detected and the timing reported, it was common for differences in height and weight to
become apparent at the same time.14, 21, 27, 31 The change in weight, however, was also
observed before 9 and after 13, 24, 30 differences in height.
Of the 6 papers in which weight-for-height was evaluated, 5 detected lower weight-for-
height among HIV-infected children compared to sero-reverters. The difference in weight-
for-height Z score ranged from −0.22 to −0.36 Z at 6 mo, −0.01 to −0.08 Z at 12 mo, and
−0.58 to −0.70 Z at 18 mo after birth. McKinney et al14 did not detect an association
between HIV infection and weight-for-length Z score with over 2 ys of follow up. The
timing of observed differences in weight-for-height were concurrent with differences in both
weight and height in 2 studies 12, 15 and occurred after such changes in 2 others.9, 30 In the
large European Collaborative Study, significant height-adjusted differences in weight
detected at 3 mo after birth did not persist beyond 12 mo.21 Two studies evaluated the
association of HIV infection and BMI and found BMI to be lower in HIV-infected children
compared to sero-reverters in the first 6 mo of life.10, 12
Other measures—No difference in head circumference-for-age was observed in HIV-
infected children vs. sero-reverters in 3 of 5 studies that evaluated this outcome.12, 13, 19,
21, 27 An early study from the United States by Miller et al15 was the only longitudinal
analysis examining changes in body composition in HIV-infected children over time. The
rates of change in muscle mass, measured by arm muscle circumference and tricep skinfold
thickness, were found to be lower in HIV-infected children compared to sero-reverters. The
rates of change in arm muscle circumference and tricep skinfold thickness were 2 mm / mo
and 0.89 mm / mo lower in HIV-infected children, respectively. A cross-sectional analysis
of a follow-up study of hemophiliac boys found no difference in triceps skinfold thickness
between HIV-infected and -uninfected boys.16
HIV exposure and postnatal growth—There is less evidence on the association
between HIV exposure (as opposed to HIV infection) and postnatal growth, with only 7
papers evaluating the growth of HIV-exposed but - uninfected children in developed country
settings (Table 2).
Linear growth—Four studies examined differences in height-for-age by HIV exposure
status. The European Collaborative Study detected no difference in height-for-age between
sero-reverters and the reference population,31 and Ross et al26 and Pollack et al 19 found
no difference in linear growth between sero-reverters and healthy controls. A smaller Italian
study observed lower height-for-age in sero-reverters compared to healthy controls, with
mean height-for-age Z scores 0.06 Z, 0.26 Z, and 0.46 Z lower in sero-reverters at 6, 12, and
24 mo of age, respectively.11 Lipman et al32 reported a greater risk of growth failure
(defined as height-for-age Z < −2, growth < 4 cm/year or height deceleration of > 10%)
among sero-reverters compared to the reference population.
Weight gain—No study observed a difference in weight gain between HIV-exposed
children and healthy controls. The weight-for-height and BMI of sero-reverters were
examined by 1 and 2 studies, respectively.10, 11, 26 In the Italian studies, both weight-for-
height and BMI were found to be higher among the sero-reverters in the first few months
after birth, but these differences decreased with time. By 4 mo of age, sero-reverters had
similar weight-for-height and BMI as healthy controls. Ross et al26 found no difference in
BMI or change in BMI over 36 mo of follow-up.
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Other measures—The association between HIV exposure and head circumference-for-
age Z scores was assessed in 1 study, where no significant difference between sero-reverters
and healthy controls was observed.19
Less developed countries
HIV infection and postnatal growth—Fifteen studies evaluated the association of HIV
infection and postnatal growth in less developed country settings (Table 3). The majority of
these reports were from sub-Saharan Africa, with only 3 studies identified from outside of
the region. The duration of follow-up ranged from 4 mo to 8 years.
Linear growth—Of the 10 studies in which height-for-age was examined, a negative
association was consistently detected in all 4, 7, 8, 17, 28, 33–36 but one study.37 In studies
in which an association was found and results reported, height-for-age Z score was lower in
HIV-infected children vs. sero-reverters by 0.23 to 1.55 Z at 6 mo, 0.25 to 0.72 Z at 12 mo,
0.44 to 1.53 Z at 18 mo after birth, and 0.68 to 1.53 Z at 24 mo after birth. Differences in
height-for-age detected as early as 3 mo of age 7, 8, 34 and before 1 y 4, 17, 33, 35 persisted
throughout follow up. HIV infection was also associated with lower gains in length velocity
(−2.8 cm / y, 95% CI: −5.0, −0.6) among children 6 to 11 mo of age in Tanzania,38 and
HIV-infected adolescents in Brazil experienced greater decreases in height-for-age Z scores
between their first and last measurement under follow-up than expected in the general
population.36
Weight gain—A negative association between HIV infection and weight gain was detected
in all 10 studies in which this relationship was evaluated. The difference in weight-for-age Z
score ranged from −0.20 to −1.72 Z at 6 mo, −0.17 to −0.87 Z at 12 mo, −0.87 to −1.43 Z
at 18 mo and −0.69 to −1.07 Z at 24 mo after birth. HIV infection was also associated with
lower yearly gains in weight among children aged 6 to 11 mo (−1.26 kg, 95% CI: −2.53,
0.02) and 12 to 23 mo (−0.59 kg, 95% CI: −1.05, −0.12) at baseline in Tanzania38 and with
an increased risk of growth disturbance, defined as weight-for-age < 5th percentile or no
weight gain in 3 mo, in Kenya.22 The decrease in weight-for-age Z score from first to last
measurement under follow-up was also larger among HIV-infected adolescents than
expected in the general population (ΔWAZ: −0.31).36 Differences in weight-for-age
between groups was detected most consistently at the same time as differences in height-for-
age,4, 7, 8, 34 though 2 studies observed the change in weight several months before
differences in height were apparent.17, 33
The link between weight-for-height by infection status was inconsistent in the 6 studies that
evaluated this outcome. Two studies provide supportive evidence of a negative association
between weight-for-height and HIV infection. In these studies, the difference in weight-for-
height between HIV-infected children and sero-reverters ranged from −0.22 to −0.92 Z at 6
mo, −0.04 to −0.50 Z at 12 mo, −0.61 to −0.91 Z at 18 mo and −0.27 Z at 24 mo after birth.
In both studies, these differences were detected 6 or more months after differences in height-
or weight-for age became apparent. Four studies found no difference in weight-for-height in
HIV-infected children compared to sero-reverters.7, 28, 34, 37 In 3 of these studies, no
difference in weight-for-height was detected, despite significant differences in height-for-
age and/or weight-for-age.7, 28, 34
Other measures—One study examined head circumference-for-age and observed smaller
head circumferences among HIV-infected children vs. sero-reverters from 3 to 30 mo of age.
7 The relative risk of failure to thrive among HIV-infected children vs. sero-reverters was
assessed in 2 studies, with observed relative risks of 2.25 at 1 y and 46.57 at 2 y in Zambia 6
and 4.48 (95% CI: 2.57, 7.81) in South Africa.18
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HIV exposure and postnatal growth—In the 6 studies to evaluate the association
between HIV exposure and postnatal growth in less developed country settings, a lack of
association was fairly consistent between HIV exposure and height-for-age,7, 8, 17, 39
weight-for-age,7, 8, 17, 20, 39, weight-for-height 8 and head circumference-for-age (Table
4).7 The only exception was 1 study from Kenya in which height-for-age Z scores were
found to be significantly lower at 1.5 mo after birth (−0.19 Z vs. −0.48 Z) and weight-for-
height Z score greater at 6 mo (0.10 Z vs. 0.45Z ) and 18 mo after birth (−0.73 Z vs. −0.16
Z) among sero-reverters compared to children born to HIV-negative mothers.37
Strengths and limitations of studies—A number of strengths and limitations
characterize the existing studies on HIV and postnatal growth. These are discussed below.
Exposure assessment—The method and frequency of assessing HIV infection status in
children is particularly relevant in the context of less developed countries, where
transmission can continue to occur after birth through breastfeeding. In these settings, it is
important to use tests for the presence of HIV antibodies (ELISA and Western blot assays)
at 15 or 18 mo of age in conjunction with more specific tests for presence of the virus
(polymerase chain reaction assays) at younger ages to account for the time-varying nature of
infection status owing to such postnatal transmission. Approximately half of the studies
conducted in less developed country settings did not describe the such of such methods for
exposure assessment nor account for the timing of transmission in the analysis.6, 7, 17, 18,
20, 22, 33, 34 Only one recent study by Webb et al35 used information from repeated PCR
measures to account for the timing of transmission in the statistical analysis of differences in
growth.
Insufficient exposure assessment also limited the interpretation of findings from one study
from Zambia. In Makasa et al,39 infants’ infection status was not determined through
laboratory methods. Analyses to evaluate the impact of HIV infection were limited to
comparisons of postnatal growth by maternal infection status among children who appeared
uninfected at the later follow-up and did not allow for explicit differentiation between HIV-
infected children and sero-reverters in the analysis.
Length of follow up—Most studies evaluated the short-term effects of HIV on postnatal
growth. Data beyond two ys of age are limited, and follow-up less than 6 mo found in some
studies 9, 10, 39 may not be long enough to capture the complete pattern of change in
growth outcomes. Only 2 studies from sub-Saharan Africa report growth beyond 2 ys. In the
one study with follow-up from birth, the later effects of HIV on growth were found to be
less than those earlier in life,7 but this result may be due to the lower survival of those most
affected. One European cohort found significant weight and height deficits at 10 ys.31 The 6
studies that enrolled children at older ages may provide some indication of the patterns of
growth among HIV-infected and HIV-exposed children later in childhood.16, 24, 25, 28, 32,
36
Sample Size—Studies often included a small number of subjects and were affected by
considerable drop out, limiting the reliability of conclusions at later time points.27, 37 Ten
studies from developed country settings 9, 10, 12, 13, 15, 19, 24, 25, 27, 29 and 8 from less
developed countries 6, 7, 18, 20, 28, 34, 37, 38 included approximately 50 or fewer HIV-
positive children.
Choice of comparison group—Poor growth in children needs to be interpreted in the
context of the health, care and social environment. In evaluating the impact of HIV
infection, nearly all studies in this review include comparisons of growth patterns between
HIV-infected and HIV-exposed but uninfected children. This choice of comparison group
Isanaka et al. Page 6
Nutr Rev. Author manuscript; available in PMC 2009 November 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
appropriately controls for many of the differences in socioeconomic status and social
background that may exist between children of HIV-positive and HIV-negative mothers,
although it is unable to separate the effects of HIV infection from social factors. The design
of 5 studies additionally allowed for comparison groups to be selected with consideration for
other factors that may affect postnatal growth, by matching on maternal age or parity 7, 8,
12 or selecting healthy controls to be formula-fed as were children born to HIV-infected
mothers.10, 11
Studies from developed settings were less likely than those from less developed settings to
include appropriate healthy, population-based controls; as a result, there are fewer studies
that use HIV-uninfected children born to HIV-negative mothers to describe the impact of
HIV exposure (not infection) from developed countries (Table 2 and Table 4). Three studies
were found to compare the growth of HIV-infected children with ‘HIV-uninfected children,’
where sero-reverters could not be distinguished from healthy controls among the latter.6, 28,
38
Limited evidence for body composition endpoints—Information on body
composition, including the distribution of fat and lean body mass, of children is important to
characterize how the nutritional status of children changes with HIV infection. This review
identified only 1 study that has evaluated changes in body composition in HIV-infected
children over time.15 The cross-sectional evidence on the relationship between HIV
infection and exposure and body composition appears similarly limited.16, 40–43
Statistical methods—The study design and repeated measures used in longitudinal
studies generally require data analysis methods that account for the correlation in repeated
measurements and the increase in variability in weight and height with age. These more
advanced models were successfully applied in 12 studies,4, 12, 13, 15, 17, 21, 26, 29–32,
35, 38 but more than half of the reviewed studies did not account for the longitudinal nature
of the data.6–11, 14, 19–21, 24, 25, 27, 28, 33, 34, 37, 39, 44 Control for factors that may
influence growth was also inconsistent across studies. Potential confounding due to
covariates associated with growth, such as birth weight, gestational age, gender, dietary
intake and maternal factors, was not controlled for in the majority of studies 6, 9, 10, 13–15,
17, 19, 20, 23, 24, 27, 29, 30, 32–34, 37, 44 but were considered in others.4, 7, 8, 11, 12, 16,
21, 25, 26, 28, 31, 35, 38, 39
Comments
Taken together, the data available can be used to highlight a number implications for clinical
practice, as well as suggest possible mechanisms of HIV-related growth failure. The data
suggest that HIV infection is associated with profound and long-lasting defects in weight
and height throughout infancy and childhood. The current evidence indicates that
differences in growth patterns become apparent by 3 to 4 mo of age, persist and perhaps
increase with time. Wasting associated with HIV infection was less common than stunting
or underweight. It is possible that HIV-infected children experience nearly proportional
declines in both height and weight such that normal weight-for-height is maintained7, 34 or
that wasting in HIV-infected children may become apparent only as children become more
sick. The data available also reveal no significant differences in the early growth of sero-
reverters and healthy controls, suggesting that viral exposure without infection does not
affect growth. These patterns of growth faltering were similar across developed and less
developed country settings, despite differences in access to supplemental feeding and
antiretroviral therapy and other factors including women’s routes of transmission, virus sub-
types, and prevalence of STDs, drug use and nutritional deficiencies.
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It was common for differences in weight-for-age to become apparent at the same time as
differences in height-for-age in both developed and less developed country settings. As
weight is more likely to fall off before height in conditions of protein-energy malnutrition,
this pattern of concurrent impairment of weight and height could indicate that other
mechanisms may underlie HIV-related growth failure. Possible mechanisms include HIV-
related disturbances to energy balance,40, 43, 45–48 gastrointestinal disturbance and
malabsorption,49–52 and nuero-endocrine changes.28, 53–58 Growth failure also may occur
as a direct result of HIV infection, independent of the variety of secondary illnesses that
accompany infection.30, 59–61
Understanding of the temporal course and mechanisms of growth impairment through future
longitudinal study will continue to be important for the early intervention and care of HIV-
infected children if impaired growth precedes and contributes to the onset of immune
deficiency and opportunistic infection. Further research in a number of specific areas
continues to be warranted to broaden and deepen our current understanding of the impact of
HIV on postnatal growth. This includes development of evidence on the effect of HIV
infection on body composition in children. As noted above, few studies have addressed the
association between HIV infection and exposure and body composition in children. These
limited studies suggest that HIV-infected children experience a preferential loss of lean body
mass compared to fat, similar to that seen in adults.62 As changes in body composition may
be an additional risk factor for disease progression, further study is needed to describe
changes in body composition in HIV-infected children over time.
Evaluation of the effect of HIV infection on adolescent growth and development should also
remain a research priority. Advances in the management of HIV means that many
perinatally infected children reach adolescence. Only a small number of studies, however,
have examined the effect of HIV on adolescent growth and pubertal development to date.41,
63, 64 Given the increasing survival of this population and the limited information on the
effect of HIV on growth and development after 4 years of age, more information on how
HIV infection may interact with adolescent growth and maturation is needed. Evaluation of
the effect of nutritional intervention / supplementation on growth, immune status and disease
progression in children is similarly important. The well-known interaction between nutrition
and immune function suggests that nutritional interventions may have the potential to limit
morbidity and mortality in HIV-infected individuals.65 The role of micronutrient status on
HIV infection has been examined in several trials in adults and children,66 though more
information on the effectiveness of various macronutrient interventions is still required.
Finally, evidence on the effect of ARV therapy on growth and body composition in HIV-
infected children must continue to be developed and summarized. ARV therapy has
improved the virological, immunological and clinical outcomes of HIV-infected children,
and studies on its effects on growth are now becoming available.61, 67, 68 Additional
efforts to develop and consolidate information on the effects of such treatment on growth
and body composition in the long-term and in less developed country settings are required.
Conclusion
Poor growth is common among children infected with HIV, and as a contributor to immune
dysfunction, it is associated with disease progression and decreased survival. In this review,
we aimed to characterize and quantify the effect of HIV infection and exposure on growth in
children. There appears to be little difference in the early growth of HIV-exposed but
uninfected and healthy controls, however, abnormal growth patterns in HIV-infected
children have been documented in both developed and less developed country settings. A
variety of disturbed growth patterns have been described, with disturbances in both height
and weight among HIV-infected children often apparent as early as 3 mo of age and
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increasing with time. Owing to the close association of growth with immune function and
clinical progression among HIV-infected children, an understanding of the growth patterns
of HIV-infected children may represent an important tool in targeting children for further
assessment. Timely growth monitoring may be used to identify those with sub-optimal
growth, ensure the provision of appropriate care and treatment to these children, and help
improve their clinical course and quality of life.
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